A Case of Advanced Gastric Cancer with Long-Term Survival Due to Successful Ramucirumab and Paclitaxel Therapy
Ono, Y.; Aoyama, T.; Morita, J.; Maezawa, Y.; Amano, S.; Sawazaki, S.; Numata, M.; Tamagawa, H.; Sato, T.; Oshima, T.; Yoshikawa, T.; Ozawa, Y.; Yukawa, N.; Masuda, M.; Rino, Y.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(13): 2156-2158
2018
ISSN/ISBN: 0385-0684 PMID: 30692316 Document Number: 695356
This is a case of a 70-year-old man. Two courses of docetaxel/cisplatin/S-1 combination therapy were administered after clinical trial registration with diagnosis of Stage Ⅳ gastric cancer(ypT3N3aM1). In June 2014, gastrectomy and splenectomy were performed. Postoperative S-1 adjuvant chemotherapy was administered; however, in September 2014, aorticl ymph node metastasis was diagnosed as recurrent. After recurrence, irinotecan/cisplatin therapy was administered. In February 2015, recurrent lymph node metastasis increased, and chemotherapy was changed to paclitaxel. In May 2015, numbness (Grade 2)of the fingers was observed, and treatment was changed to oxaliplatin/S-1. In February 2016, storage of ascites became remarkable; therefore, chemotherapy was discontinued as per policy. After that, we continued outpatient visit and observed increased recurrent lymph node metastasis on image evaluation; however, as the patient's general condition was good, chemotherapy was restarted. Ramucirumab/paclitaxel therapy started in February 2017. During the course of treatment, neutropenia(Grade 2)was observed as an adverse event, but therapy continuation was possible without loss of ramucirumab only with loss of paclitaxel. Thereafter, the recurrence of lymph node metastasis was reduced, and the ascites accumulation decreased. Until now, 1 year after the start of ramucirumab/paclitaxel therapy, the patient still visits the outpa- tient clinic.